Description: Phathom Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. It develops Vonoprazan, a potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Buffalo Grove, IL.
Home Page: www.phathompharma.com
PHAT Technical Analysis
100 Campus Drive
Florham Park,
NJ
07932
United States
Phone:
877 742 8466
Officers
| Name | Title |
|---|---|
| Ms. Terrie J. Curran | Pres, CEO & Director |
| Mr. David A. Socks | Co-Founder & Director |
| Dr. Azmi Nabulsi M.D., M.P.H. | Co-Founder & COO |
| Mr. Anthony J. Guzzo | Chief Accounting Officer |
| Mr. Aditya Kohli Ph.D. | Co-Founder |
| Ms. Molly Henderson CPA, MBA | Chief Financial & Bus. Officer |
| Mr. Joseph Hand J.D. | Chief Admin. Officer |
| Mr. Lawrence Miller Esq., J.D. | Gen. Counsel & Sec. |
| Mr. Tom Harris | Chief Devel. Sciences Officer |
| Dr. Eckhard Leifke M.D., Ph.D. | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 6.6361 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2019-10-25 |
| Fiscal Year End: | December |
| Full Time Employees: | 77 |